Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
41
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 39.50 | -0.44% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 22,934.68 | 717.19 | -3.03% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,907.84 | 1,713.40 | -2.65% |
| NZX 50 Index | 13,718.91 | 27.93 | -0.20% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,793.20 | 38.10 | -0.43% |
| SSE Composite Index | 3,658.03 | 55.00 | -1.48% |